Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability of BI 1358894 Formulations in Healthy Subjects
NCT05155306Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Jan 2022
- Primary completion
- May 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of bi 1358894 in major depressive disorder (MDD) and borderline personality disorder (BPD) (4 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Area Under the Concentration-time Curve in Plasma 0 to Last Quantifiable Data Point and Maximum Measured Concentration in Plasma. Started Jan 2022; status: completed.
02
Drugs
bi 1358894
03
Conditions
major depressive disorder (MDD)borderline personality disorder (BPD)
Beyond the preview
Go deeper on NCT05155306.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05155306.